The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer

<div class="floats-full-page floats-full-page-other"><h2>Table 1</h2><div class="floats-full-page-caption"><div>Clinicopathological parameters for patients (<span class="nowrap"><svg height="8.55521pt" id="M9" style="vertical-align:-0.2063904pt" version="1.1" viewbox="-0.0498162 -8.34882 40.3636 8.55521" width="40.3636pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M495 86L479 114C446 82 419 66 409 66C401 66 401 72 406 97C420 166 436 231 453 297C489 435 454 448 428 448C406 448 384 439 354 422C305 394 222 327 161 247H159L183 345C200 415 194 448 173 448C143 448 82 410 23 351L38 325C64 349 95 371 105 371C111 371 116 365 109 336L25 -4L31 -12C50 -4 77 3 107 9C119 69 132 122 145 168C197 254 321 381 370 381C387 381 393 374 378 305L329 95C309 17 320 -12 345 -12C372 -12 430 19 495 86Z"></path></g><g transform="matrix(.013,0,0,-0.013,10.158,0)"><path d="M535 323V373H52V323H535ZM535 138V188H52V138H535Z"></path></g><g transform="matrix(.013,0,0,-0.013,21.421,0)"><path d="M384 0V27C293 34 287 42 287 114V635C232 613 172 594 109 583V559L157 557C201 555 205 550 205 499V114C205 42 199 34 109 27V0H384Z"></path></g><g transform="matrix(.013,0,0,-0.013,27.661,0)"><path d="M384 0V27C293 34 287 42 287 114V635C232 613 172 594 109 583V559L157 557C201 555 205 550 205 499V114C205 42 199 34 109 27V0H384Z"></path></g><g transform="matrix(.013,0,0,-0.013,33.901,0)"><path d="M249 635C141 635 70 555 70 471C70 401 114 353 179 316C143 294 106 267 90 252C68 231 45 202 45 157C45 50 130 -12 237 -12C322 -12 435 52 435 169C435 256 372 304 303 343C349 374 375 398 383 407C401 429 411 458 411 487C411 569 344 635 249 635ZM238 603C285 603 337 567 337 482C337 422 310 385 276 358C205 393 145 426 145 500C145 552 179 603 238 603ZM248 20C183 20 125 70 125 163C125 218 158 268 206 300C284 261 355 217 355 143C355 66 308 20 248 20Z"></path></g></svg>).</span></div></div><div class="floats-full-page-content"><table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr /></td></tr><tr class="thead"><td class="align_left">Clinicopathological parameter</td><td class="align_center"><svg height="6.1673pt" id="M10" style="vertical-align:-0.2063904pt" version="1.1" viewbox="-0.0498162 -5.96091 6.6501 6.1673" width="6.6501pt" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><g transform="matrix(.013,0,0,-0.013,0,0)"><path d="M495 86L479 114C446 82 419 66 409 66C401 66 401 72 406 97C420 166 436 231 453 297C489 435 454 448 428 448C406 448 384 439 354 422C305 394 222 327 161 247H159L183 345C200 415 194 448 173 448C143 448 82 410 23 351L38 325C64 349 95 371 105 371C111 371 116 365 109 336L25 -4L31 -12C50 -4 77 3 107 9C119 69 132 122 145 168C197 254 321 381 370 381C387 381 393 374 378 305L329 95C309 17 320 -12 345 -12C372 -12 430 19 495 86Z"></path></g></svg> (%)</td></tr><tr><td class="thead-hr" colspan="2"><hr /></td></tr><tr><td class="align_left">Age (years)</td><td class="align_left"></td></tr><tr><td class="align_left"> ≤70</td><td class="align_center">50 (42.4%)</td></tr><tr><td class="align_left"> &gt;70</td><td class="align_center">68 (57.6%)</td></tr><tr><td class="align_left">Preoperative PSA level (ng/ml)</td><td class="align_left"></td></tr><tr><td class="align_left"> &lt;10</td><td class="align_center">34 (28.8%)</td></tr><tr><td class="align_left"> 10-20</td><td class="align_center">20 (16.9%)</td></tr><tr><td class="align_left"> &gt;10</td><td class="align_center">64 (54.3%)</td></tr><tr><td class="align_left">Gleason score</td><td class="align_left"></td></tr><tr><td class="align_left"> 2-6</td><td class="align_center">33 (28.0%)</td></tr><tr><td class="align_left"> 7</td><td class="align_center">30 (25.4%)</td></tr><tr><td class="align_left"> 8-10</td><td class="align_center">55 (46.6%)</td></tr><tr><td class="align_left">pT stage</td><td class="align_left"></td></tr><tr><td class="align_left"> ≤T2</td><td class="align_center">71 (60.1%)</td></tr><tr><td class="align_left"> &gt;T2</td><td class="align_center">47 (39.9%)</td></tr><tr><td class="align_left">Metastasis</td><td class="align_left"></td></tr><tr><td class="align_left"> Absent</td><td class="align_center">75 (63.6%)</td></tr><tr><td class="align_left"> Present</td><td class="align_center">43 (36.4%)</td></tr><tr><td class="align_left">Hormone therapy</td><td class="align_left"></td></tr><tr><td class="align_left"> No</td><td class="align_center">87 (73.7%)</td></tr><tr><td class="align_left"> Yes</td><td class="align_center">31 (26.3%)</td></tr><tr><td class="align_left">Follow-up</td><td class="align_left"></td></tr><tr><td class="align_left"> Alive</td><td class="align_center">61 (51.7%)</td></tr><tr><td class="align_left"> Dead</td><td class="align_center">25 (21.2%)</td></tr><tr><td class="align_left"> Loss</td><td class="align_center">32 (27.1%)</td></tr><tr><td class="align_left">Surgical intervention</td><td class="align_left"></td></tr><tr><td class="align_left"> Prostatectomy</td><td class="align_center">71 (60.2%)</td></tr><tr><td class="align_left"> TURP</td><td class="align_center">47 (39.8%)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr" /></td></tr></table></td></tr><tr class="table-fn"><td><div>Abbreviations: pT stage: pathologic tumor stage; PSA: prostate-specific antigen; TURP: Transurethral Resection of the Prostate.<br /></div></td></tr></table></div></div>

Table 1 | The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer

title

Table 1: The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer

description

Table 1

About this journal

<p><em>BioMed Research International</em> publishes original research articles and&nbsp;review articles covering a wide range of subjects within the biomedical sciences. The journal will accept both basic and translational research.</p>


Journal profile

Meet the editorial board

<p><em>BioMed Research International</em> maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.</p>


Editor spotlight

Submit to Special Issue

We currently have a number of Special Issues open for submission. Special Issues highlight emerging areas of research within a field, or provide a venue for a deeper investigation into an existing research area.

Special Issues

Author guidelines

Editorial board

Databases and indexing

BioMed Research International publishes original research articles and review articles covering a wide range of subjects within the biomedical sciences. The journal will accept both basic and translational research.